secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0001023024-25-000024
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharmaceuticals buys out perpetual royalty on ILUVIEN/YUTIQ for $17.25M
---------------------------------------------------------------------------

- Paid $17.25M one-time cash to SWK to eliminate 3.125% perpetual royalty on worldwide net revenues of ILUVIEN and YUTIQ.
- No further royalty due from January 1, 2025 forward; buyout covers all future net revenues.
- Funded with cash on hand; enhances financial flexibility for Retina portfolio growth.
- CEO Nikhil Lalwani states the transaction reflects commitment to maximizing long-term value of ILUVIEN and YUTIQ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302425000024/0001023024-25-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302425000024/ani-20250318.htm
  HTML page:      https://secwatch.observer/filing/0001023024-25-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer